Sanara MedTech(SMTI)

Search documents
Sanara MedTech to Report Second Quarter 2025 Financial Results on August 13, 2025
Globenewswire· 2025-07-15 20:05
FORT WORTH, TX, July 15, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced it will report its second quarter 2025 financial results on Wednesday, August 13, 2025 before the U.S. financial markets open. The Company will host a conference call an ...
Sanara MedTech Inc. Announces Launch of Tissue Health Plus Wound Care Provider Pilot Program
Globenewswire· 2025-07-14 20:05
Core Insights - Sanara MedTech Inc. has launched a pilot program through its subsidiary Tissue Health Plus (THP) aimed at providing value-based wound care solutions for chronic wounds across six states [1][2] - The THP technology platform will serve as a Wound Care Operating System for a provider group, utilizing Co-Pilot software to standardize patient care and streamline administrative processes [2] - The pilot program is expected to validate and optimize the THP technology platform through real-world patient encounters, with plans for expansion to additional practitioners and locations [2] Company Overview - Sanara MedTech Inc. focuses on developing and commercializing technologies to improve clinical outcomes and reduce healthcare costs in surgical and chronic wound markets [4] - The company markets a range of surgical and wound care products primarily in the North American market, including CellerateRX Surgical Activated Collagen and various antimicrobial solutions [4][5] - THP aims to transform the $100+ billion wound care market by addressing gaps in chronic wound care, with a goal of improving healing rates to over 85% and reducing total care costs by more than 25% [3] Technology and Innovation - THP's platform combines AI-powered clinical decision support, virtual care coordination, and an integrated provider network to deliver personalized wound care [3] - The pilot program is part of a broader strategy to engage with payers and financial partners to support the implementation of THP's value-based care solutions [2][3]
Sanara MedTech(SMTI) - 2025 Q1 - Earnings Call Presentation
2025-06-13 08:55
Sanara MedTech Investor Presentation Disclaimers This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the "Company," "Sanara," "we," "our" or "us"). All statements other than statements of historical fact contained herein are forward-looking statements. These statements may be identified by terms such as "aims," "anticipates," "believes," "c ...
Sanara MedTech: Pursuing Rapid Expansion While Debt Levels Climb
Seeking Alpha· 2025-06-09 10:22
Group 1 - Sanara MedTech (SMTI) shares have faced pressure this year despite strong growth and improving profitability in the Surgical segment, primarily due to concerns over rising debt levels [1] - The company operates in a sector that is often under-researched, focusing on small to mid-cap companies with potential asymmetric investment opportunities [1] Group 2 - The article reflects the author's personal investment experience and analysis, emphasizing the importance of thorough research in identifying market-beating returns [1]
Sanara MedTech(SMTI) - 2025 Q1 - Quarterly Report
2025-05-14 20:02
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-39678 SANARA MEDTECH INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employ ...
Sanara MedTech Inc. (SMTI) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-05-14 13:51
Financial Performance - Sanara MedTech Inc. reported a quarterly loss of $0.41 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.31, and compared to a loss of $0.21 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $23.43 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 5.32%, and showing an increase from year-ago revenues of $18.54 million [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.29 on revenues of $25.35 million, and for the current fiscal year, it is -$1.78 on revenues of $107.2 million [7] - The estimate revisions trend for Sanara MedTech is mixed, leading to a Zacks Rank 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6] Market Performance - Sanara MedTech shares have increased by approximately 5.7% since the beginning of the year, outperforming the S&P 500, which gained only 0.1% [3] - The outlook for the industry, specifically the Medical - Products sector, is currently in the bottom 31% of over 250 Zacks industries, which may impact the stock's performance [8]
Sanara MedTech(SMTI) - 2025 Q1 - Earnings Call Transcript
2025-05-14 13:02
Sanara MedTech (SMTI) Q1 2025 Earnings Call May 14, 2025 08:00 AM ET Company Participants Ron Nixon - CEO & Executive ChairmanSeth Yon - President of CommercialSam Muppalla - CEOElizabeth Taylor - CFOYi Chen - Managing Director, Equity ResearchMatthew Park - Equity Research Associate Operator Welcome to the Sonera MedTech First Quarter of twenty twenty five Earnings Conference Call. Please note that this conference call is being recorded and a replay will be available on the Investor Relations page of the c ...
Sanara MedTech(SMTI) - 2025 Q1 - Earnings Call Transcript
2025-05-14 13:00
Sanara MedTech (SMTI) Q1 2025 Earnings Call May 14, 2025 08:00 AM ET Speaker0 Welcome to the Sonera MedTech First Quarter of twenty twenty five Earnings Conference Call. Please note that this conference call is being recorded and a replay will be available on the Investor Relations page of the company's website shortly. The company issued its earnings release earlier today. Before we begin, I would like to remind everyone that certain statements on today's call include forward looking statements within the ...
Sanara MedTech(SMTI) - 2025 Q1 - Quarterly Results
2025-05-14 11:15
Financial Performance - Net revenue for Q1 2025 increased by 26% year-over-year to $23.4 million, up from $18.5 million in Q1 2024[5] - Gross profit for Q1 2025 was $21.6 million, a 30% increase from $16.6 million in Q1 2024, with a gross margin of 92%[9] - Net revenue for the three months ended March 31, 2025, was $23,434,096, representing a 26.5% increase from $18,536,638 in the same period of 2024[24] - Gross profit for the same period was $21,599,129, up from $16,646,592, indicating a gross margin improvement[24] - Segment Adjusted EBITDA for the total was $657,969 for Q1 2025, compared to $311,421 in Q1 2024, reflecting an increase of approximately 111%[32] - Segment Adjusted EBITDA as a percentage of Net Revenue for Q1 2025 was 2.8%, up from 1.7% in Q1 2024, showing improved operational efficiency[32] Expenses and Losses - Operating expenses increased by 30% to $23.7 million, driven by a 32% rise in selling, general and administrative expenses[10] - Net loss for Q1 2025 was $3.5 million, compared to a net loss of $1.8 million in Q1 2024[13] - Operating loss increased to $2,080,029 for Q1 2025 compared to a loss of $1,531,707 in Q1 2024[24] - Net loss attributable to Sanara MedTech shareholders was $3,527,177 for Q1 2025, compared to $1,764,184 in Q1 2024, reflecting a significant increase in losses[24] - The net loss for the three months ended March 31, 2025, was $(3,527,383), compared to $(1,799,043) in the prior year, indicating a significant increase in losses[32] - Net Loss as a percentage of Net Revenue for Q1 2025 was (15.1)%, compared to (9.7)% in Q1 2024, indicating a worsening loss margin[32] Cash and Debt Management - As of March 31, 2025, the company had $20.7 million in cash and $42.8 million in principal debt obligations[15] - Total current assets rose to $36,842,548 as of March 31, 2025, compared to $33,305,988 at the end of 2024, driven by an increase in cash and inventory[22] - Long-term debt increased to $43,402,223 as of March 31, 2025, up from $30,689,290 at the end of 2024, indicating higher leverage[22] - Cash at the end of the period was $20,687,806, a significant increase from $15,878,295 at the end of 2024, reflecting improved cash flow management[26] - Total liabilities increased to $59,711,004 as of March 31, 2025, compared to $49,180,030 at the end of 2024, indicating a rise in financial obligations[22] Product Sales and Initiatives - Sales of soft tissue repair products rose by 28% to $20.5 million, while bone fusion products increased by 18% to $2.9 million[8] - Sanara plans to launch its first pilot program for the Tissue Health Plus initiative in Q2 2025 and is seeking financial partners for this strategy[6] - The company aims to address the large surgical greenfield opportunity and improve profitability in its Sanara Surgical segment throughout 2025[6] Research and Development - Research and development expenses for Q1 2025 were $1,114,138, compared to $946,298 in Q1 2024, highlighting continued investment in innovation[24] Other Financial Metrics - Adjusted EBITDA for Q1 2025 was $0.7 million, up from $0.3 million in Q1 2024, with the Sanara Surgical segment contributing $2.7 million[14] - Interest expense for Q1 2025 was $1,317,092, compared to $267,336 in Q1 2024, highlighting a significant increase in financing costs[32] - Noncash share-based compensation for Q1 2025 totaled $1,304,904, compared to $803,386 in Q1 2024, indicating an increase of approximately 62%[32] - Acquisition costs for Q1 2025 amounted to $308,684, reflecting ongoing investment in growth strategies[32] - Depreciation and amortization expenses for Q1 2025 were $1,124,410, compared to $1,105,420 in Q1 2024, showing a slight increase[32] - The share of losses from equity method investments was $143,608 for Q1 2025, with no losses reported in Q1 2024, indicating new challenges in equity investments[32]
Sanara MedTech to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
Newsfilter· 2025-04-10 20:00
Core Viewpoint - Sanara MedTech Inc. is set to present at the Planet MicroCap Showcase: VEGAS 2025, highlighting its focus on developing transformative medical technologies aimed at improving clinical outcomes and reducing healthcare costs in surgical, chronic wound, and skincare markets [1] Company Overview - Sanara MedTech Inc. specializes in medical technology, focusing on the development and commercialization of innovative products to enhance clinical outcomes and lower healthcare expenditures [3] - The company markets and distributes a range of surgical, wound, and skincare products primarily in the North American advanced wound care and surgical tissue repair markets [3] - Key products include CellerateRX® Surgical Activated Collagen®, FORTIFY TRG® Tissue Repair Graft, and various advanced biologic products such as ACTIGEN® Verified Inductive Bone Matrix and BIASURGE® Advanced Surgical Solution [3] - Sanara also offers telemedicine services for wound care and dermatology consultations, aiming to improve patient outcomes while managing costs [3] Upcoming Presentation - Management will present to investors on April 23, 2025, at approximately 3:30 p.m. Pacific Time during the Planet MicroCap Showcase [1] - Presentation materials will be available on the company's investor relations website prior to the event, along with a live audio webcast and an archive for later access [2]